Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Idarubicin-lipiodol adjuvant therapy after percutaneous ablation for small hepatocellular carcinoma
2019-001362-15Phase 2Terminated
- Sponsor
- Centre Hospitalier Universitaire de Montpellier
- Start
- Jul 2019
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of idarubicin and ethiodized oil in hepatocellular carcinoma (HCC) (2 arms), sponsored by Centre Hospitalier Universitaire de Montpellier. Primary endpoint: Hepatic recurrence-free survival at 1 year. Started Jul 2019; status: terminated.
02
Drugs
idarubicinethiodized oil
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2019-001362-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001362-15.